-

Vetoquinol Receives FDA Approval for Felpreva™ in the USA

LURE, France--(BUSINESS WIRE)--Regulatory News:

Vetoquinol (Paris:VETO) announces that Felpreva™ received approval from the U.S. Food & Drug Administration (FDA). Felpreva™ is a broad‑spectrum parasiticide designed specifically for cats which is applied just four times a year in a topical dose.

“We are excited to bring Felpreva™ to U.S. veterinarians and cat owners,” said Matthieu Frechin, Chairman and Chief Executive Office of Vetoquinol. “Felpreva™ takes the complexity out of parasite control for both veterinarians and cat owners by providing a straightforward solution: fewer applications with broad-spectrum treatment and control.”

In the USA as well as in Europe, Felpreva™ is a prescription-only product for feline use exclusively. Since it was first launched in the European Union in 2022, Felpreva™ has been trusted by veterinarians and cat owners.

Next release: 2026 annual sales, January 14, 2027 (after market close)

ABOUT VETOQUINOL
Vetoquinol is a leading international player in animal health, with operations in Europe, the Americas and Asia/Pacific.
Independent and pure player, Vetoquinol innovates, develops and markets veterinary medicines and non-medicated products for farm animals (cattle, pigs) and companion animals (dogs, cats).
Since its creation in 1933, Vetoquinol has combined innovation and geographic diversification. The strengthening of the product portfolio and acquisitions in high-potential territories ensure hybrid growth for the Group. As of June 30, 2026, Vetoquinol employed 2,526 people.

Vetoquinol has been listed on Euronext Paris since 2006 (ticker symbol: VETO).
The Vetoquinol share is eligible for the French PEA and PEA-PME personal equity plans.

Contacts

FOR MORE INFORMATION, PLEASE CONTACT:

VETOQUINOL

Investor Relations
Josette Molle-Yukna
Phone: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

Vetoquinol

BOURSE:VETO

Release Versions

Contacts

FOR MORE INFORMATION, PLEASE CONTACT:

VETOQUINOL

Investor Relations
Josette Molle-Yukna
Phone: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

More News From Vetoquinol

Vetoquinol: Sales at End September 2026

LURE, France--(BUSINESS WIRE)--Regulatory News: Vetoquinol (Paris:VETO): Sales for the third quarter of 2026 totaled €140 million, up +10.4% compared to the prior year on a reported basis and +9.6% at constant exchange rates, driven by a favorable currency impact of €1 million from the U.S. and the Americas excluding the U.S. The company’s business was driven by the Essentials segment, which grew by +13.9% on a reported basis and +12.9% at constant exchange rates. Business was solid in most reg...

Vetoquinol: 2026 Half Year Results

LURE, France--(BUSINESS WIRE)--Regulatory News: Matthieu Frechin, Chairman and CEO of Vetoquinol (Paris:VETO), stated: “The results for the first half of fiscal year 2026 confirm the strength of our business model, with a return to growth in our business, strong momentum for our Essential products, rising profitability, and robust cash flow generation. We are actively preparing our next growth drivers, with several new product launches on the horizon.” The Board of Directors of Vetoquinol SA, m...

Vetoquinol: Availability of the 2025 Universal Registration Document

LURE, France--(BUSINESS WIRE)--Regulatory News: On 29 April 2026, Vetoquinol (Paris:VETO) filed its 2025 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). The 2025 Universal Registration Document in ESEF and PDF formats (reproduction of the official version of the Universal Registration Document in ESEF format) is available to the public under the conditions provided by applicable regulations and may be consulted on the “...
Back to Newsroom